Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2

Status

Completed 13Recruiting 11Unknown 5Not yet recruiting 5Withdrawn 3Terminated 3Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Thoracic 1

Conditions

Breast Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × neratinib × Clear all
NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
21 enrolled 15 charts
Breast

Breast Neoplasms

NCT01953926 2024-03-12

SUMMIT

Puma Biotechnology, Inc.

Phase 2 Terminated
582 enrolled 27 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT04460430 2022-10-25

NEREA

SOLTI Breast Cancer Research Group

Phase 2 Terminated
12 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡